🇪🇺 STIMUFEND in European Union

EMA authorised STIMUFEND on 28 March 2022

Marketing authorisation

EMA — authorised 28 March 2022

  • Application: EMEA/H/C/004780
  • Marketing authorisation holder: Fresenius Kabi Deutschland GmbH
  • Local brand name: Stimufend
  • Indication: Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
  • Pathway: biosimilar
  • Status: approved

Read official source →

STIMUFEND in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is STIMUFEND approved in European Union?

Yes. EMA authorised it on 28 March 2022.

Who is the marketing authorisation holder for STIMUFEND in European Union?

Fresenius Kabi Deutschland GmbH holds the EU marketing authorisation.